Citations

Clear

4206 citation(s) found for "Yu, Chen".

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Campone, Mario , Sohn, Joohyuk , Paluch–Shimon, Shani , Huober, Jens , Park, In Hae , Trédan, Olivier , Chen, Shin‐Cheh , Manso, Luís , Freedman, Orit, Jaliffe, Georgina Garnica, Forrester, Tammy , Frenzel, Martin, Barriga, Susana , Bourayou, Nawel, Leo, Angelo Di , Toi, Masakazu , Paluch-Shimon, Shani, Freedman, Orit C, Garnica Jaliffe, Georgina, Smith, Ian C., Di Leo, Angelo, Hae Park, In , Di Leo, Angelo , Goetz, Matthew P. , Smith, Ian C., Manso Sanchez, Luis , Sohn, Joohyuk

Mayo Clinic

Journal of Clinical Oncology | October 2, 2017 | Volume: 35 | Issue: 32 | Pages: 3638-3646

10.1200/jco.2017.75.6155 | PMID 28968163 Get It

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Comprehensive Characterization of Alternative Polyadenylation in Human Cancer
Xiang, Yu , Ye, Youqiong , Lou, Yanyan , Zhang, Zhao , Chen, Ning-Yuan, Kim, Yoon-Jin , Ozguc, Fatma Muge, Diao, Lixia , Xia, Yang, Kellems, Rodney E. , Shyu, Ann‐Bin, Mills, Gordon B. , Han, Leng , Ye, Youqiong , Han, Leng , Mills, Gordon B , Yang, Yang , Cai, Chunyan C. , Mills, Tingting , Chen, Ning‐Yuan, Karmouty‐Quintana, Harry , Xia, Yang, Chen, Zheng , Blackburn, Michael R. , Yoo, Seung Hee

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 25, 2017 | Volume: 110 | Issue: 4 | Pages: 379-389

10.1093/jnci/djx223 | PMID 29106591 Get It

Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke)
Froehler, Michael T. , Zaidat, Osama O., Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Liebeskind, David S, Jadhav, Ashutosh P. , Gupta, Rishi , Hassan, Ameer E , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Abou‐Chebl, Alex, Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Martin, Jerry C., Mueller‐Kronast, Nils , Liebeskind, David S. , Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Saver, Jeffrey L. , Jahan, Reza , Haussen, Diogo C , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Almandoz, Josser E Delgado , Jadhav, Ashutosh P , Derdeyn, Colin P

Mayo Clinic

Circulation | September 25, 2017 | Volume: 136 | Issue: 24 | Pages: 2311-2321

10.1161/circulationaha.117.028920 | PMID 28943516 Get It

Background: Endovascular treatment with mechanical thrombectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although treatment efficacy is highly time-dependent. We hypothesized that interhospital transfer to endovascular-capable centers would result in treatment delays and worse clinical outcomes compared with direct presentation. Methods: STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, observational, single-arm study of real-world MT for acute stroke because of anterior-circulation large-vessel occlusion performed at 55 sites over 2 years, including 1000 patients with severe stroke and treated within 8 hours. Patients underwent MT with or without intravenous tissue plasminogen activator and were admitted to endovascular-capable centers via either interhospital transfer or direct presentation. The primary clinical outcome was functional independence (modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of stroke care delivery, (2) outcome differences between direct and transfer patients undergoing MT, and (3) the potential impact of local hospital bypass. Results: A total of 984 patients were analyzed. Median onset-to-revascularization time was 202.0 minutes for direct versus 311.5 minutes for transfer patients ( P <0.001). Clinical outcomes were better in the direct group, with 60.0% (299/498) achieving functional independence compared with 52.2% (213/408) in the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P =0.02). Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4% (236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13–1.92; P =0.005). Mortality did not differ between the 2 groups (15.1% for direct, 13.7% for transfer; P =0.55). Intravenous tissue plasminogen activator did not impact outcomes. Hypothetical bypass modeling for all transferred patients suggested that intravenous tissue plasminogen activator would be delayed by 12 minutes, but MT would be performed 91 minutes sooner if patients were routed directly to endovascular-capable centers. If bypass is limited to a 20-mile radius from onset, then intravenous tissue plasminogen activator would be delayed by 7 minutes and MT performed 94 minutes earlier. Conclusions: In this large, real-world study, interhospital transfer was associated with significant treatment delays and lower chance of good outcome. Strategies to facilitate more rapid identification of large-vessel occlusion and direct routing to endovascular-capable centers for patients with severe stroke may improve outcomes. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis
Miura, Fumihiko, Okamoto, Kohji , Takada, Tadahiro , Strasberg, Steven M. , Asbun, Horacio J. , Pitt, Henry A. , Gomi, Harumi , Solomkin, Joseph S. , Schlossberg, David, Kim, Myung‐Hwan , Hwang, Tsann‐Long , Chen, Miin‐Fu , Huang, Wayne Shih‐Wei, Kiriyama, Seiki , Itoi, Takao , Garden, O. James , Liau, Kui‐Hin, Liu, Keng‐Hao, Su, Cheng‐Hsi, Gouma, Dirk J., Belli, Giulio, Dervenis, Christos, Jagannath, P., Chan, Angus C. W., Lau, Wan Yee , Endo, Itaru , Santibáñes, Eduardo de , Giménez, Mariano , Jonas, Eduard , Singh, Harjit , Asai, Koji , Mori, Yasuhisa , Wada, Keita, Higuchi, Ryota , Rikiyama, Toshiki, Kano, Nobuyasu, Umezawa, Akiko , Tokumura, Hiromi, Hata, Jiro , Kozaka, Kazuto , Iwashita, Yukio , Hibi, Taizo , Yokoe, Masamichi, Kimura, Taizo, Kitano, Seigo, Inomata, Masafumi , Sumiyama, Yoshinobu, Inui, Kazuo, Yamamoto, Masakazu , Han, Ho-Seong , Horiguchi, Akihiko , Suzuki, Kenji S. , Yoon, Yoo-Seok , Honda, Goro , Watanabe, Manabu , Sata, Naohiro , Mukai, Shuntaro , Hirata, Koichi , Jonas, Eduard

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | September 23, 2017 | Volume: 25 | Issue: 1 | Pages: 31-40

10.1002/jhbp.509 | PMID 28941329 Get It

AbstractThe initial management of patients with suspected acute biliary infection starts with the measurement of vital signs to assess whether or not the situation is urgent. If the case is judged to be urgent, initial medical treatment should be started immediately including respiratory/circulatory management if required, without waiting for a definitive diagnosis. The patient's medical history is then taken; an abdominal examination is performed; blood tests, urinalysis, and diagnostic imaging are carried out; and a diagnosis is made using the diagnostic criteria for cholangitis/cholecystitis. Once the diagnosis has been confirmed, initial medical treatment should be started immediately, severity should be assessed according to the severity grading criteria for acute cholangitis/cholecystitis, and the patient's general status should be evaluated. For mild acute cholangitis, in most cases initial treatment including antibiotics is sufficient, and most patients do not require biliary drainage. However, biliary drainage should be considered if a patient does not respond to initial treatment. For moderate acute cholangitis, early endoscopic or percutaneous transhepatic biliary drainage is indicated. If the underlying etiology requires treatment, this should be provided after the patient's general condition has improved; endoscopic sphincterotomy and subsequent choledocholithotomy may be performed together with biliary drainage. For severe acute cholangitis, appropriate respiratory/circulatory management is required. Biliary drainage should be performed as soon as possible after the patient's general condition has been improved by initial treatment and respiratory/circulatory management. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.
Immobilization of vitronectin‐binding heparan sulfates onto surfaces to support human pluripotent stem cells
Yap, Lynn , Murali, Sadasivam, Bhakta, Gajadhar, Chen, Allen Kuan‐Liang, Sim, Lyn Chiin, Lim, Yu Ming , Goh, James Cho‐Hong , Oh, Steve , Choo, Andre , Wijnen, André J. van , Robinson, David E., Whittle, Jason D. , Short, Robert D. , Nurcombe, Victor , Cool, Simon M. , van Wijnen, Andre J , Titmarsh, Drew M. , Bardor, Muriel , Birch, William R.

Mayo Clinic

Journal of Biomedical Materials Research Part B: Applied Biomaterials | September 20, 2017 | Volume: 106 | Issue: 5 | Pages: 1887-1896

10.1002/jbm.b.33999 | PMID 28941021 Get It

AbstractFunctionalizing medical devices with polypeptides to enhance their performance has become important for improved clinical success. The extracellular matrix (ECM) adhesion protein vitronectin (VN) is an effective coating, although the chemistry used to attach VN often reduces its bioactivity. In vivo, VN binds the ECM in a sequence‐dependent manner with heparan sulfate (HS) glycosaminoglycans. We reasoned therefore that sequence‐based affinity chromatography could be used to isolate a VN‐binding HS fraction (HS9) for use as a coating material to capture VN onto implant surfaces. Binding avidity and specificity of HS9 were confirmed by enzyme‐linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR)‐based assays. Plasma polymerization of allylamine (AA) to tissue culture‐treated polystyrene (TCPS) was then used to capture and present HS9 as determined by radiolabeling and ELISA. HS9‐coated TCPS avidly bound VN, and this layered surface supported the robust attachment, expansion, and maintenance of human pluripotent stem cells. Compositional analysis demonstrated that 6‐O‐ and N‐sulfation, as well as lengths greater than three disaccharide units (dp6) are critical for VN binding to HS‐coated surfaces. Importantly, HS9 coating reduced the threshold concentration of VN required to create an optimally bioactive surface for pluripotent stem cells. We conclude that affinity‐purified heparan sugars are able to coat materials to efficiently bind adhesive factors for biomedical applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1887–1896, 2018.
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma
Davila, Jaime , Starr, Jason S. , Attia, Steven , Knudson, Ryan A., Necela, Brian M. , Sarangi, Vivekananda , Sun, Zhifu , Ren, Yingxue , Casler, John D., Menke, David M. , Oliver, Gavin R. , Copland, John A. , Parker, Alexander S. , Kocher, Jean-Pierre A., Thompson, E. Aubrey , Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime I, Sun, Zhifu , Davila, Jaime I , Wang, Chen , Joseph, Richard W.

Mayo Clinic

Rare Tumors | September 15, 2017 | Volume: 9 | Issue: 2 | Pages: 50-53

10.4081/rt.2017.6834 | PMID 28975018 Get It

We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity of this disease, there are no personalized and molecularly targeted treatment options due to the lack of knowledge in the genomic makeup of the tumor. A 44-year-old white woman was diagnosed with an extranodal FDCS in thyroid. The patient underwent a total thyroidectomy, central compartment dissection, parathyroid re-implantation, and adjuvant radiation therapy. Tumor DNA sequencing of 236 genes by FoundationOne panel found truncating mutations in PTEN and missense mutations in RET and TP53. However, patient-matched germline DNA was not sequenced which is critical for identification of true somatic mutations. Furthermore, the FoundationOne panel doesn't measure genomic rearrangements which have been shown to be abundant in sarcomas and are associated with sarcoma tumorigenesis and progression. In the current study, we carried out comprehensive genomic sequencing of the tumor, adjacent normal tissues, and patient-matched blood, in an effort to understand the genomic makeup of this rare extranodal FDCS and to identify potential therapeutic targets. Eighty-one somatic point mutations were identified in tumor but not in adjacent normal tissues or blood. A clonal truncating mutation in the CLTCL1 gene, which stabilizes the mitotic spindle, was likely a driver mutation of tumorigenesis and could explain the extensive copy number aberrations (CNAs) and genomic rearrangements in the tumor including a chr15/chr17 local chromothripsis resulted in 6 expressed fusion genes. The fusion gene HDGFRP3→SHC4 led to a 200-fold increase in the expression of oncogene SHC4 which is a potential target of the commercial drug Dasatinib. Missense mutations in ATM and splice-site mutation in VEGFR1 were also detected in addition to the TP53 missense mutation reported by FoundationOne.
Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience
Botero, Juliana Perez , Coon, Lea M., Majerus, Julie A. , Chen, Dong , Pruthi, Rajiv K. , Perez Botero, Juliana , Chen, Dong

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 14, 2017 | Volume: 44 | Issue: 03 | Pages: 287-292

10.1055/s-0037-1605567 | PMID 28905352 Get It

AbstractIn hemophilia B (HB), factor IX gene (F9) genotyping is used for molecular confirmation of affected individuals, for carrier testing, to facilitate the identification of those at risk for anaphylaxis/inhibitors (associated with large deletions), and to assist in assigning disease severity. Owing to test costs, optimal test utilization involves pre/post-test counseling and appropriate patient and test selection (e.g., mutation screening [F9MS] vs. known mutation [F9KM] testing). This article aims to review the trends and outcomes of F9-genotyping orders and describe the spectrum of variants identified in a sample of individuals in our reference laboratory. We performed a retrospective review of consecutive orders submitted to the Special Coagulation DNA Diagnostic Laboratory, Mayo Clinic, between 2012 and 2015. A total of 133 orders (38%) were identified for men: 118 (88%) were F9MS and 15 (12%) were F9KM. Thirteen orders (10%) were cancelled. A total of 209 orders were identified for women: 178 (85%) were F9MS and 31 (15%) were F9KM. Thirty-seven orders (18%) were cancelled and 30% of the tests performed yielded negative results. A total of 164 samples (47%) were received without clinical information. Seventeen previously unreported variants were identified. F9 genotyping provides useful information for HB management; however, 18% of our orders were cancelled and almost half were received without relevant clinical information, thus reaffirming the need for ongoing scrutiny of submitted orders. Optimal patient and test selection is important as is the accurate interpretation of variants identified. Most of the pathogenic variants identified were point mutations, with very few large deletions, consistent with the literature.
The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension
Chen, Libo , Larsen, Carolyn , Le, Rachel J., Connolly, Heidi M. , Pislaru, Sorin V. , Murphy, Joseph G. , McGoon, Michael D., Frantz, Robert P. , Kane, Garvan C. , Larsen, Carolyn M , Sabbah, Michael S. , Frantz, Robert P

Mayo Clinic

The Clinical Respiratory Journal | September 14, 2017 | Volume: 12 | Issue: 4 | Pages: 1572-1580

10.1111/crj.12713 | PMID 28905517 Get It

AbstractIntroductionTricuspid valve regurgitation (TR) is a frequent finding in patients with pulmonary arterial hypertension (PAH). However, its prognostic significance and relation to PAH, while suspected, are poorly understood. We assessed 727 consecutive patients with newly diagnosed PAH who underwent transthoracic echocardiographic evaluation of tricuspid valve function.ObjectivesThe study objective was to determine the association of TR presence and severity with patient characteristics, pulmonary artery hemodynamics and outcome.MethodsConsecutive patients with newly diagnosed PAH (N = 727 with group 1 pulmonary hypertension) underwent transthoracic echocardiographic evaluation of tricuspid valve function at diagnosis. The primary study end point was all‐cause mortality or lung transplantation.ResultsIn this population, 702 patients (96.5%) had TR; in 165 patients (23%), TR was severe. Compared with those with no or mild TR by echocardiography criteria, patients with severe TR had shorter mean (SD) 6‐minute walk distances (285 [125] m vs 360 [121] m; P = .02) and higher levels of B‐type natriuretic peptide (695 [672] pg/dL vs 328 [300] pg/dL; P < .05). Severe TR was associated with greater right atrial dilatation (91% vs 47%; P = .004) and right ventricular (RV) dilatation (92% vs 51%; P = .008), greater right atrial pressure (mean [SD] 15 [7] mm Hg vs 10 [6] mm Hg; P < .001) and lower cardiac index (mean [SD], 2.2 [0.7] L/min/m2 vs 2.8 [0.9] L/min/m2; P < .001). Severe TR was strongly predictive of greater 5‐year mortality risk after adjustment for age, sex, functional class, 6‐minute walk distance, diffusing capacity, RV size and pulmonary vascular resistance index (adjusted hazard ratio, 1.83; 95% CI, 1.38‐2.41; P < .001).ConclusionsSevere TR was a significant predictor of long‐term mortality rate in PAH, and TR severity correlated with PAH severity.
Preliminary results of tissue‐engineered injection laryngoplasty material in a rabbit model
Oldenburg, Michael , Ekbom, Dale C. , Marina, Serban San, Voss, Steve, Chen, Tiffany , García, Joaquín J. , Janus, J.R., Oldenburg, Michael S , San Marina, Serban, Garcia, Joaquin, Janus, Jeffery R

Mayo Clinic

The Laryngoscope | September 12, 2017 | Volume: 128 | Issue: 1 | Pages: 160-167

10.1002/lary.26849 | PMID 28895165 Get It

Objectives/HypothesisDesign and test a novel biomaterial for injection laryngoplasty aimed to increase the duration of effectiveness of micronized acellular dermis.Study DesignAnimal model.MethodsInjection laryngoplasty was performed in three groups (n = 5) of New Zealand White rabbits. Acellular dermis was either used alone as a control (group 1), was combined with undifferentiated stem cells (group 2), or with predifferentiated chondrocytic cells (group 3). Groups 2 and 3 were supplemented with growth factors. Animals were sacrificed 4 and 12 weeks after laryngoplasty and histologic analysis was completed. The major outcome measure was volume of tissue remaining.ResultsAfter 4 weeks, the mean volume of tissue remaining was 341 ± 89 mm3, 295 ± 102 mm3, and 133 ± 15 mm3, for groups 1 to 3, respectively. At the 12‐week time point, volumes were 62 ± 62 mm3, 235 ± 35 mm3, and 107 ± 99 mm3. After 12 weeks, there was a significantly higher volume in group 2 compared to group 1 or 3 (P = .01, P = .04). Volumes between week 4 and week 12 were significantly lower in group 1 (P = .02), but not significantly different for groups 2 and 3 (P = .38, P = .74). Histologic evaluation revealed a robust lymphocytic infiltration in all cases as well as morphologic and immunophenotypic features suggestive of chondrogenic differentiation in a single animal.ConclusionsMicronized acellular dermis combined with stem cells and growth factors showed significantly less resorption 12 weeks after injection laryngoplasty compared to micronized acellular dermis alone. Groups using novel tissue‐engineered biomaterial showed a lower resorption rate over time compared with acellular dermis alone.Level of EvidenceNA. Laryngoscope, 128:160–167, 2018
Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma
Pašić, Ivan , Wong, Kit Man , Lee, Jonghun J., Espin‐Garcia, Osvaldo , Brhane, Yonathan , Cheng, Dangxiao , Patel, Devalben, Brown, Catherine , Bucur, Roxana , Reisman, David , Knox, Jennifer J. , Hung, Rayjean J., Liu, Geoffrey , Cleary, Sean P. , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Cleary, Sean P , Chen, Zhuo , Xu, Wei , Knox, Jennifer J

Mayo Clinic

Molecular Carcinogenesis | September 11, 2017 | Volume: 57 | Issue: 1 | Pages: 106-113

10.1002/mc.22736 | PMID 28892201 Get It

Polymorphisms in the promoter of the BRM gene, a critical subunit of the chromatin remodeling SWI/SNF complex, have previously been implicated in risk and prognosis in Caucasian‐predominant lung, head and neck, esophageal, and pancreatic cancers, and in hepatocellular cancers in Asians. We investigated the role of these polymorphisms in hepatocellular carcinoma (HCC) risk and prognosis. HCC cases were recruited in a comprehensive cancer center while the matched controls were recruited from family practice units from the same catchment area. For risk analyses, unconditional logistic regression analyses were performed in HCC patients and matched healthy controls. Overall survival analyses were performed using Cox proportional hazard models, Kaplan‐Meier curves, and log‐rank tests. In 266 HCC cases and 536 controls, no association between either BRM promoter polymorphism (BRM‐741 or BRM‐1321) and risk of HCC was identified (P > 0.10 for all comparisons). There was significant worsening of overall survival as the number of variant alleles increased: BRM‐741 per variant allele adjusted hazards ratio (aHR) 5.77, 95% confidence interval (CI) 2.89‐11.54 and BRM‐1321 per variant allele aHR 4.09, 95%CI 2.22‐7.51. The effects of these two polymorphisms were at least additive, where individuals who were double homozygotes for the variant alleles had a 45‐fold increase in risk of death when compared to those who were double wild‐type for the two polymorphisms. Two BRM promoter polymorphisms were strongly associated with HCC prognosis but were not associated with increased HCC susceptibility. The association was strongest in double homozygotes for the allele variants.